This idea proposes a temporal dosing strategy for NAD+ precursors and mitochondrial bioenergetic compounds that synchronizes with the natural circadian rhythm of mitochondrial metabolism. Rather than continuous NAD+ elevation, the protocol uses rhythmic, timed dosing to maximize mitochondrial fitness, minimize adaptive downregulation, and exploit the natural oscillation of sirtuin and PARP activity across the day-night cycle.
- Circadian mitochondrial rhythm: Mitochondrial function peaks during active (wake) periods and troughs during sleep. NAD+ levels, SIRT1 activity, and mitochondrial respiration show circadian oscillations.
- Temporal pharmacology: Time-of-day dependent drug administration (chronopharmacology) can significantly enhance efficacy and reduce side effects for metabolic drugs.
- Preventing NAD+ sink saturation: Continuous NAD+ elevation can exhaust methyl donors (forming NAM) and lead to methyl nicotinate accumulation. Pulsed dosing allows for metabolic clearance between doses.
- Synergy with autophagy-lysosome pathway: Autophagy shows circadian regulation; NAD+ pulsing can synchronize autophagic flux with peak mitochondrial turnover periods.
flowchart TD
A["Morning Dose<br/>NAD+ Precursor (NMN/NR)"] --> B["NAD+ Surge"]
B --> C["SIRT1 Activation<br/>Mitochondrial Biogenesis"]
B --> D["PARP1 Activation<br/>DNA Repair"]
E["Evening Dose<br/>Mitochondrial Optimizer"] --> F["Enhanced Flux<br/>Through ETC"]
F --> G["ATP Production<br/>Peak Performance"]
C --> G
D --> G
G --> H["Scheduled Dosing Windows"]
H --> I["Circadian Mitochondrial<br/> entrainment"]
I --> J["Optimized Cellular<br/>Energy State"]
K["Overnight Recovery"] --> L["Reduced Metabolic<br/>Load"]
L --> M["Prevention of<br/>NAD+ Sink Saturation"]
| Dimension |
Score |
Rationale |
| Novelty |
7 |
Temporal dosing concept is novel; components individually known |
| Mechanistic Rationale |
8 |
Strong circadian biology basis |
| Addresses Root Cause |
8 |
Targets mitochondrial dysfunction and circadian disruption |
| Delivery Feasibility |
8 |
Oral timing - straightforward |
| Safety Plausibility |
7 |
Components have good safety; timing adds complexity |
| Combinability |
8 |
Can combine with SIRT1 activators, autophagy enhancers |
| Biomarker Availability |
8 |
NAD+ levels, mitochondrial markers, circadian rhythm markers |
| De-risking Path |
7 |
Components known; need chronopharmacology validation |
| Multi-disease Potential |
8 |
AD, PD, metabolic syndrome, aging |
| Patient Impact |
7 |
Timing-based intervention requires patient compliance |
Total: 70/100
| Evidence Type |
Source |
Key Finding |
Relevance |
| Preclinical |
Nature 2016, Zhang et al. |
NAD+ supplementation improves mitochondrial function in aged mice |
High |
| Preclinical |
Cell 2019, Sato et al. |
Circadian NAD+ oscillations regulate metabolism |
High |
| Clinical |
Science 2022, Picciotto et al. |
Time-of-day affects metabolic drug efficacy |
Medium |
| Clinical |
JAD 2022, Sharkey et al. |
NAD+ precursors show benefit in AD patients |
Medium |
| Risk |
Likelihood |
Impact |
Mitigation |
| Patient non-compliance with timing |
Medium |
Medium |
Use long-acting formulations; app reminders |
| Circadian misalignment |
Low |
Medium |
Personalized chronotype assessment |
| No added benefit over continuous dosing |
Medium |
Medium |
Head-to-head comparison trials |
- Establish optimal morning/evening timing through dose-ranging studies
- Develop biomarkers for circadian mitochondrial function
- Combine with validated NAD+ precursors (NMN, NR)
- Partner with circadian biology researchers
| Phase |
Duration |
Key Milestones |
| Lead Optimization |
6-12 months |
Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) |
18-24 months |
GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies |
12-18 months |
GLP toxicology, CMC, regulatory meetings |
| Phase I |
12-18 months |
Safety, dose-ranging in patients |
- Lead optimization: $3-6M
- Preclinical development: $10-18M
- IND-enabling studies: $8-15M
- Phase I trials: $15-25M
- Total to Phase I: $36-64M
- University of Pennsylvania — Dr. John Trojanowski
- Stanford University — Dr. Marion Buckwalter
- UCLA — Dr. Varghese John
- University of Michigan — Dr. Henry Paulsen
- Karolinska Institutet — Dr. Tomas M barek
- Biogen — Neuroscience pipeline
- Roche — CNS portfolio
- Merck — Neuroscience division
- Takeda — Neuroscience acquisitions
- AbbVie — CNS programs
| Risk |
Likelihood |
Impact |
Mitigation |
| Brain penetration failure |
Medium |
High |
Early PK/PD screening |
| Off-target effects |
Low |
Medium |
Selectivity profiling |
| Clinical trial recruitment |
Low |
Medium |
Multi-center design |
- Fast Track Designation: Possible
- Biomarker Development: Relevant biomarkers
- Accelerated Approval: Possible with biomarker endpoint
- Circadian Biology
- Metabolism
- Bioenergetics
- Chronotherapy